LiveHealth

livehealth.in

LiveHealth enables better interaction between Healthcare Providers, Doctors and Patients on one platform making access to organised medical information easy and seamless. For Healthcare Providers, we offer Information Systems (IS) for Diagnostics & Laboratories, which make medical information management easier, seamless and mobile without the overheads of IT Infrastructure and development. We help you grow easily, scale to multiple locations with just a few clicks and monitor and manage your operations in real time, right from your mobile.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

CTA APPROVAL OF BIOINVENT'S BI-1808, A FIRST-IN-CLASS ANTI-TNFR2 ANTIBODY, SETS STAGE FOR PHASE I/IIA TRIAL

BioInvent | October 27, 2020

news image

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has received regulatory authority approval of its clinical trial application (CTA) in Denmark for a Phase I/IIa, first-in-human study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)...

Read More

INDUSTRIAL IMPACT

NEXEO PLASTICS AND EARTH RENEWABLE TECHNOLOGIES SIGN AGREEMENT TO DISTRIBUTE BIOCOMPOUNDS IN NORTH AMERICA

Nexeo Plastics | March 02, 2022

news image

Nexeo Plastics, a leading global thermoplastics resin distributor, has announced an agreement with Earth Renewable Technologies, Inc. (ERT), a biotechnology company, to distribute ERT’s BioCompounds in Canada and the United States. “We are extremely pleased to collaborate with ERT to increase the slate of sustainable products we offer our customers. ERT’s BioCompounds complement the products we already carry and help us close the gap in our ...

Read More

MEDICAL

SALIPRO BIOTECH OBTAINS GRANTED PATENTS IN THE UNITED STATES AND CHINA FOR DIRECT EXTRACTION OF MEMBRANE PROTEINS AND LIBRARY GENERATION

Salipro Biotech | September 08, 2022

news image

Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled "Saposin lipoprotein particles and libraries from crude membranes" has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration. The patents cover the company's novel method of direct extraction of membrane proteins from cells or crude ...

Read More

MEDTECH

AEGLEA BIOTHERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR PEGZILARGINASE

Aeglea BioTherapeutics, Inc. | August 19, 2022

news image

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that a Marketing Authorization Application for pegzilarginase for the treatment of Arginase 1 Deficiency has been submitted to and successfully validated by the European Medicines Agency. The MAA was submitted by Immedica Pharma AB, Aeglea's commercialization partner in Europe and the Middle East. <...

Read More
news image

CELL AND GENE THERAPY

CTA APPROVAL OF BIOINVENT'S BI-1808, A FIRST-IN-CLASS ANTI-TNFR2 ANTIBODY, SETS STAGE FOR PHASE I/IIA TRIAL

BioInvent | October 27, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has received regulatory authority approval of its clinical trial application (CTA) in Denmark for a Phase I/IIa, first-in-human study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)...

Read More
news image

INDUSTRIAL IMPACT

NEXEO PLASTICS AND EARTH RENEWABLE TECHNOLOGIES SIGN AGREEMENT TO DISTRIBUTE BIOCOMPOUNDS IN NORTH AMERICA

Nexeo Plastics | March 02, 2022

Nexeo Plastics, a leading global thermoplastics resin distributor, has announced an agreement with Earth Renewable Technologies, Inc. (ERT), a biotechnology company, to distribute ERT’s BioCompounds in Canada and the United States. “We are extremely pleased to collaborate with ERT to increase the slate of sustainable products we offer our customers. ERT’s BioCompounds complement the products we already carry and help us close the gap in our ...

Read More
news image

MEDICAL

SALIPRO BIOTECH OBTAINS GRANTED PATENTS IN THE UNITED STATES AND CHINA FOR DIRECT EXTRACTION OF MEMBRANE PROTEINS AND LIBRARY GENERATION

Salipro Biotech | September 08, 2022

Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled "Saposin lipoprotein particles and libraries from crude membranes" has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration. The patents cover the company's novel method of direct extraction of membrane proteins from cells or crude ...

Read More
news image

MEDTECH

AEGLEA BIOTHERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR PEGZILARGINASE

Aeglea BioTherapeutics, Inc. | August 19, 2022

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that a Marketing Authorization Application for pegzilarginase for the treatment of Arginase 1 Deficiency has been submitted to and successfully validated by the European Medicines Agency. The MAA was submitted by Immedica Pharma AB, Aeglea's commercialization partner in Europe and the Middle East. <...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us